Astrazeneca (AZN) Other financing activities (2010 - 2026)

Astrazeneca's Other financing activities history runs 15 years deep, the most recent figure standing at $2.3 billion for Q1 2026.

• In Q1 2026, Other financing activities rose 112.37% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $1.6 billion (up 2286.57% YoY), while the FY2025 annual figure was $364.0 million, up 1274.19% from the prior year.
• Other financing activities was $2.3 billion for Q1 2026 at Astrazeneca, up from -$1.0 billion in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $2.3 billion in Q1 2026 to a low of -$1.9 billion in Q3 2024.
• Historically, Other financing activities has averaged $235.0 million across 5 years, with a median of $97.0 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Other financing activities tumbled 266.67% in 2023, then soared 6108.0% in 2024.
• A 5-year view of Other financing activities shows it stood at $15.0 million in 2022, then sank by 266.67% to -$25.0 million in 2023, then sank by 2312.0% to -$603.0 million in 2024, then slumped by 68.82% to -$1.0 billion in 2025, then soared by 329.27% to $2.3 billion in 2026.
• The last three Other financing activities figures came in at $2.3 billion (Q1 2026), -$1.0 billion (Q4 2025), and -$352.0 million (Q3 2025), per Business Quant data.